6 Shandong Minhe Animal Husbandry Co.Ltd(002234) / 14 the annual report of 2021 was released. The company achieved an operating revenue of 12.363 billion yuan, a total profit of 644 million yuan and a net profit attributable to the owner of the parent company of 362 million yuan. As of December 31, 2021, the total assets of the company were 61.415 billion yuan, and the net assets attributable to the owners of the parent company were 4.727 billion yuan. The company plans to pay cash dividends to all shareholders based on the total share capital, and distribute cash dividends of 1.1 yuan (including tax) for every 10 shares, with a total dividend of 111 million yuan.
According to the data of the annual report, in 2021, although the performance of the company’s health real estate business declined due to the impact of the market downturn, the company’s other business segments improved rapidly, the transformation to the health industry was obvious, and the proportion of income and profit of biomedical sector increased. In 2021, Shandong Furuida Pharmaceutical Group Co., Ltd. (consolidated basis) achieved an operating revenue of 2.181 billion yuan, a year-on-year increase of 66.74%, accounting for 17.64% of the company’s operating revenue and an increase of 8.03 percentage points over the previous year; The total profit was 223 million yuan, a year-on-year increase of 75.12%, accounting for 34.64% of the total profit of the company, accounting for an increase of 19.72 percentage points over the previous year; The net profit attributable to the owners of the parent company was 180 million yuan, a year-on-year increase of 69.29%, accounting for 49.68% of the net profit attributable to the owners of the parent company, an increase of 33.05 percentage points over the previous year.
Among all business segments, the growth rate of cosmetics business is particularly eye-catching. In 2021, the company’s cosmetics business achieved an annual operating revenue of 1.49 billion yuan, a year-on-year increase of 117%. Among them, the performance of Yilian and Dr. yu’er brands increased rapidly. Yilian brand achieved an annual operating revenue of 646 million yuan, a year-on-year increase of 73.08%, and Dr. yu’er achieved an annual operating revenue of 744 million yuan, a year-on-year increase of 272.14%. Based on the prospective research on the prospect of the cosmetics industry and its own development potential, Shandong Furuida Pharmaceutical Group Co., Ltd. started the construction of Zhimei science and technology innovation park project in 2019. The first phase of the project is a new cosmetics factory, which was completed and put into operation in 2021. The industrial park plans 35 water bottles, facial mask, spray and sub throw production lines, and the annual output value will exceed 4 billion yuan, which will meet the demand of Jinyu Bio-Technology Co.Ltd(600201) for the next 3-5 years.
During the reporting period, the company continued to increase R & D investment. In 2021, the company invested 129 million yuan in R & D, a year-on-year increase of 67.22%; There were 336 R & D personnel, a year-on-year increase of 15%. The company’s R & D investment is mainly for the R & D of pharmaceutical and cosmetics business. In terms of the construction of R & D platform, focus Freida was approved as a “small giant” enterprise specializing in Texin and a “provincial enterprise technology center” supported by the state. Lushang Design Institute was successively recognized as a “small and medium-sized enterprise specializing in Texin” in Jinan and Shandong Province in 2021. Freida Jinyu Bio-Technology Co.Ltd(600201) was approved as a “provincial technological innovation demonstration enterprise”. Freida Pharmaceutical Group established three research centers with Shandong University, Jiangnan University and other universities, There are 6 R & D institutions jointly built by schools and enterprises. In terms of innovation, 42 new authorized patents, 1 first prize and 1 two Prize were awarded to the national commercial science and technology progress award. 18 of the products were imported from the focus of furida, and Jinyu Bio-Technology Co.Ltd(600201) launched the lotus leaf “fullerene” essence, Dr. Brown’s “brown algae” water emulsion, good face “mitochondria” water emulsion, iprhan Lavender night facial mask, the most herbal herbal skin care and other cosmetics 84. Lushang innovative development applied for five software copyrights and one utility model patent, and “Lushang · digital industrial port” was selected into the excellent case collection of urban renewal and existing building reconstruction in China. In terms of academic achievements, we carried out expert consensus and pharmacoeconomic evaluation of large varieties of traditional Chinese medicine, issued China’s first expert consensus on skin microecology and skin health, drafted an industry standard for skin microecology, and published a monograph on Chinese skin microecology.
In addition, the annual report pointed out that the company accelerated the pace of capital operation in 2021, completed the joint-stock transformation of its subsidiary Shandong Lushang Property Service Co., Ltd. (later renamed “Lushang life Service Co., Ltd.), started the listing of Lushang service in Hong Kong, and submitted the listing application to the Hong Kong stock exchange. Freida Jinyu Bio-Technology Co.Ltd(600201) successfully introduced five strategic investors including Guangxi Tencent Venture Capital Co., Ltd. and Nantong Zhaohua No. 2 emerging industry investment fund partnership (limited partnership), with a war investment of 738 million yuan, setting an annual record for the introduction of war investment by state-owned enterprises in Shandong Province. Furuida Pharmaceutical Group cooperated with Beijing funakon Biotechnology Co., Ltd. to establish Shandong fuzhongfu Biotechnology Co., Ltd. to layout the fullerene cosmetics raw material market; Since its establishment, Longmen Freda venture capital fund, which is a shareholder of the company, has been focusing on cutting-edge technologies such as protein drugs, nucleic acid drugs and cell therapy, and has invested in 14 projects.
For future development planning, the company has further strengthened its determination and confidence in transformation. The annual report points out that the company is positioned as China’s leading comprehensive operator of the big health industry, and resolutely transforms to the big health industry. It will make full use of the industrial resources of the group and the company, change from developers to life service providers, change from selling houses to creating a better lifestyle, take the big health as the fulcrum, pry the transformation and development to a smooth landing, and shift and upgrade the profitability.
In terms of transformation, with the help of the favorable opportunity of the three departments such as the CSRC to support the transformation of listed real estate enterprises, the goal is to transform to the health industry, especially to biomedicine, cosmetics, medical care and health care.
In terms of development, focusing on the strengthening and expansion of the biomedical sector, Freida Pharmaceutical Group will focus on the pharmaceutical and health industry, and actively build “two brands and two bases” around raw materials, innovative drugs, high-end medical devices, health products, high-end cosmetics and nursing products, that is, China’s leading brand of orthopaedic drugs, high-end skin care brand of hyaluronic acid, an important ophthalmic drug production base in China and the world’s largest hyaluronic acid raw material production base. Focusing on the “light landing” of the healthy real estate sector, the company will focus on the orderly operation of the real estate business, ensure delivery, quality, sales and payment collection, and ensure the stability of the basic market and the safety of cash flow. At the same time, make full use of existing industrial resources, extend to the upstream and downstream of the industrial chain of the real estate industry, and make a difference in asset light business fields such as property management, agent construction, commercial management and urban renewal.
